Table 4.
Associations between MUC5B risk allele and mutated genes involved in the immunity pathway.
| IPF patients without MUC5B risk allele (n = 93) | IPF patients with MUC5B risk allele (n = 17) | OR (95% CI) | P value | |
|---|---|---|---|---|
| HLA-DQB1 | 93 (100.0) | 17 (100.0) | – | – |
| HLA-B | 93 (100.0) | 17 (100.0) | – | – |
| HLA-A | 93 (100.0) | 17 (100.0) | – | – |
| SEC22B | 93 (100.0) | 17 (100.0) | – | – |
| HLA-DRB1 | 93 (100.0) | 16 (94.1) | NA | 1.000 |
| HLA-DRB5 | 92 (98.9) | 16 (94.1) | 0.17 (0.01–2.92) | 0.224 |
| HLA-H | 89 (95.7) | 17 (100.0) | NA | 0.999 |
| HLA-DQA1 | 89 (95.7) | 16 (94.1) | 0.72 (0.08–6.86) | 0.774 |
| KIR2DS4 | 78 (83.9) | 16 (94.1) | 3.08 (0.38–24.99) | 0.293 |
| ERAP1 | 75 (80.6) | 15 (88.2) | 1.80 (0.38–8.59) | 0.461 |
| KIR2DL1 | 73 (78.5) | 16 (94.1) | 4.38 (0.55–35.09) | 0.164 |
| HSPA6 | 54 (58.1) | 13 (76.5) | 2.35 (0.71–7.75) | 0.161 |
| PLA2R1 | 56 (60.2) | 8 (47.1) | 0.59 (0.21–1.66) | 0.315 |
| HLA-G | 50 (53.8) | 12 (70.6) | 2.06 (0.67–6.33) | 0.205 |
| PLCG2 | 20 (21.5) | 3 (17.6) | 0.78 (0.20–2.99) | 0.720 |
IPF = idiopathic pulmonary fibrosis. All values are reported as number and percentage. The value represented the number of the patients with rare variants in each gene. P values and odd ratio (OR) with 95% confidence intervals (CIs) were from logistic regression analysis.